Telix and Regeneron Announce Radiopharma Collaboration
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Telix will receive an upfront payment for initial programs and has the potential to earn significant milestone payments and royalties. The collaboration aims to advance precision oncology treatments and includes plans for developing radio-diagnostics to enhance patient selection and treatment assessment.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings CallTelix Pharmaceuticals Limited on 6ix
In the deck
Story so far
Earlier from Telix Pharmaceuticals
- FDA Accepts NDA for TLX101-Px (Pixclara)
- Telix Strengthens Board with Additional Director Appointments
- Q1 2026 Strong Revenue Growth and Tx Pipeline Advancement
- Telix Appoints David Gill as Non-Executive Director
- Telix selects IBA Cyclone® KIUBE to support manufacturing expansion in the U.S.
Later from Telix Pharmaceuticals
- Regeneron and Telix Announce Strategic Radiopharma Collaboration
- Telix and Regeneron Announce Strategic Radiopharma Collaboration
- Telix Refinances Convertible Bonds
- Telix Investor Presentation April 2026
- Telix Successfully Prices Upsized US$600M Convertible Bonds
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals